• Diagnosis​ Info ​and​ ​General​ ​Questions

  Gene Editing Tool in Ongoing Sickle Cell Trial of BIVV003 Supported by Early Study

  Posted by sickle-cell-forum-administrator on February 3, 2020 at 9:10 am

  

  A proof-of-concept study supports Sangamo’s ZFN gene editing technology used with the cell therapy BIVV003, now in a Phase 1/2 trial in severe SCD patients. Click here to learn more.

  What do you think of this news?

  sickle-cell-forum-administrator replied 4 years, 2 months ago 0 Member · 0 Replies
• 0 Replies

Log In to Reply